Botanix Pharmaceuticals Ltd has released a press release.
Confirmation Sofpironium Bromide NDA Formally Under Review
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- Placement Completion and Results of Share Purchase Plan
- Share Purchase Plan Opens
- A$5 million Institutional Placement and Share Purchase Plan
- Botanix receives A$3.7m R&D Tax Incentive Refund
- BOT Announces Promotion and Focus on NDA Approval Readiness
Later from Botanix Pharmaceuticals
- Appendix 4C - Quarterly
- Press Article Correction
- Half Yearly Report and Accounts
- FDA Mid-Cycle Review Meeting Successfully Completed
- Botanix Raises A$10 million via Institutional Placement
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals